Quick Study: Introduction to Tuberous Sclerosis Complex (TSC) and Epilepsy

Tuberous sclerosis complex (TSC) image

Seizures occur in up to 90 percent of people with TSC and TSC is the leading genetic cause of epilepsy. 1.

APRIL 3 - MAY 8, 2025 | 12:00 PM - 1:00 PM (EST) | THURSDAYS WEEKLY

Register

Tuberous sclerosis complex (TSC) is a multisystem disorder that can cause both epilepsy related and non-epilepsy related complications that family care providers may encounter. This curriculum aims to provide evidence-based education regarding management and treatment of TSC, TSC-associated epilepsy and other TSC comorbidities for health care providers caring for children and youth, and adults living with epilepsy.

  • Next Session

    April 24, 2025

    12:00 pm 1:00 pm

    S4. Tuberous Sclerosis Associated Neuropsychiatric Disorder

Case Support - supporting you and your patient graphic

Case Support

Healthcare providers can present your de-identified case for advice, support and written recommendations.

Submit a Case
Children's Hospital of Eastern Ontario Logo
McMaster Children's Hospital Logo

This Quick Study series is facilitated by epilepsy specialists from the Children’s Hospital of Eastern Ontario (CHEO) and McMaster Children’s Hospital.

Syllabus

  • Review the clinical diagnostic criteria for TSC, including dermatological findings
  • Describe the genetic components associated with TSC and implications for patient care
  • Describe the mechanism of action and indications for Everolimus in TSC treatment
  • Discuss the use of Everolimus for epilepsy, subependymal giant cell astrocytomas (SEGA), and AMLs
  • Explain the use of Vigabatrin in treating epilepsy associated with TSC
  • Discuss the efficacy and safety profiles of other standard ASMs in TSC
  • Define TAND and identify its manifestations in patients with TSC
  • Understand the contribution of epilepsy and ASM use to neuropsychiatric symptoms
  • Discuss management strategies to address TAND in clinical practice
  • Review surgical options, including indications and outcomes, for epilepsy management in TSC
  • Discuss non-surgical treatments for management of refractory epilepsy
  • Recognize renal angiomyolipomas (AML) and other renal manifestations of TSC
  • Assess the impact of ASM medications on renal function in patients with TSC

Didactics & Recordings

You must be logged in to view this content.


You must be logged in to view this content.

Clinical Leads

Dr. Katherine Muir, Paediatric Neurologist

Dr. Katherine Muir, Paediatric Neurologist

Medical Co-Lead | CHEO

Female Icon

Nevena Simic, Neuropsychologist

McMaster Children's Hospital

Jennifer Flinn

Jennifer Flinn, Principal (Ottawa)

TSC Canada representative

Register

NOTE: Zoom Registration is working, you will receive a Zoom email confirming registration after you complete the form. However you may also receive this onscreen message “echo.zoom.us refused to connect” after registering. Do not be concerned, we are looking into this issue. But please email us at epilepsy@echoontario.ca if you do not receive the Zoom Registration Confirmation Email within 5 minutes of registering.